アブストラクト
Japanese
| Title | アリピプラゾールによる急性アカシジア発現のリスク因子に関する臨床調査 |
|---|---|
| Subtitle | 一般論文 |
| Authors | 白濱雅史1, 石田茂1, 永田健一郎1, 渡邊裕之1, 辻敏和1, 宮崎恭輔2, 江頭伸昭1 |
| Authors (kana) | |
| Organization | 1九州大学病院薬剤部, 2九州大学病院精神科神経科 |
| Journal | 医療薬学 |
| Volume | 46 |
| Number | 8 |
| Page | 414-420 |
| Year/Month | 2020 / 8 |
| Article | 報告 |
| Publisher | 日本医療薬学会 |
| Abstract | 「緒言」アカシジアは抗精神病薬の投与によって生じる錐体外路症状の1つであり, 不安や焦燥感, 下肢のむずむず感といった主観的症状と, 落ち着きなく足を揺する, 歩き回るといった客観的症状を特徴とする. アカシジアは急性アカシジア, 遅発性アカシジア, 離脱性アカシジア, 慢性アカシジアに分類され, 最も頻度が高い急性アカシジアは抗精神病薬の開始, 増量, 抗コリン薬の中断によって生じる. 急性アカシジアの治療では原因薬剤の減量, ほかの抗精神病薬への変更が推奨されており, 必要に応じてアカシジア症状の緩和のためにβ遮断薬, 抗コリン薬やベンゾジアゼピン系薬などが用いられる. アカシジアは患者にとって不快感が強く, 治療拒否などアドヒアランス低下につながるだけでなく, 自殺衝動を高める可能性が報告されていることから, 抗精神病薬の使用に際し特に注意を要する副作用の1つとなっている. |
| Practice | 薬学 |
| Keywords | aripiprazole, acute akathisia, risk factors, extrapyramidal symptoms |
English
| Title | Identification of Risk Factors Associated with Aripiprazole-induced Acute Akathisia |
|---|---|
| Subtitle | |
| Authors | Masafumi Shirahama1, Shigeru Ishida1, Kenichiro Nagata1, Hiroyuki Watanabe1, Toshikazu Tsuji1, Kyosuke Miyazaki2, Nobuaki Egashira1 |
| Authors (kana) | |
| Organization | 1Department of Pharmacy, Kyushu University Hospital, 2Department of Neuropsychiatry, Kyushu University Hospital |
| Journal | Japanese Journal of Pharmaceutical Health Care and Sciences |
| Volume | 46 |
| Number | 8 |
| Page | 414-420 |
| Year/Month | 2020 / 8 |
| Article | Report |
| Publisher | Japanese Society of Pharmaceutical Health Care and Sciences |
| Abstract | Akathisia is one of the extrapyramidal side effects induced by antipsychotics, such as aripiprazole (ARP). Although ARP is used widely in the treatment of various psychiatric disorders, such as schizophrenia, mood disorders, and autism spectrum disorders, there is a higher risk of developing akathisia following treatment with ARP than with other second-generation antipsychotics. However, the risk factors for acute akathisia induced by individual antipsychotics, including ARP, have not been fully established. In this study, we retrospectively analyzed the risk factors for the development of acute akathisia in patients treated with ARP. In total, the study included 160 patients who received ARP between April 2010 and March 2017. We found that 16.3% of all patients (n = 26) experienced ARP-induced acute akathisia within 6 weeks of receiving the first dose. There were significant differences in age (P < 0.01), sex (P = 0.04), and diazepam equivalent dose (P < 0.01) between patient groups with and without akathisia. Moreover, multivariate analysis indicated that age (younger than or equal to 31 years of age, P < 0.01) and diazepam equivalent dose (less than or equal to 4.2 mg, P = 0.03) were relevant factors in the development of ARP-induced acute akathisia. The results of this study suggest that scrupulous clinical attention should be paid to younger patients and patients receiving a relatively low diazepam equivalent dose during treatment with ARP to prevent the development of acute akathisia. |
| Practice | Pharmaceutical sciences |
| Keywords | aripiprazole, acute akathisia, risk factors, extrapyramidal symptoms |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A 3rd, Assuncao-Talbott S, Akathisia: an updated review focusing on second-generation anti-psychotics, J Clin Psychiatry, 2009, 70, 627-643.
- 2) Barnes TR, A rating scale for drug-induced akathisia, Br J Psychiatry, 1989, 154, 672-676.
- 3) Miller CH, Fleischhacker WW, Managing antipsychotic-induced acute and chronic akathisia, Drug Saf, 2000, 22, 73-81.
- 4) Sachdev P, Research diagnostic criteria for drug-in-duced akathisia: conceptualization, rationale and proposal, Psychopharmacology(Berl), 1994, 114, 181-186.
- 5) Pringsheim T, Gardner D, Addington D, Martino D, Morgante F, Ricciardi L, Poole N, Remington G, Edwards M, Carson A, Barnes TRE, The Assess-ment and Treatment of Antipsychotic-Induced Akathisia, Can J Psychiatry, 2018, 63, 719-729.
残りの24件を表示する
- 6) Stroup TS, Gray N, Management of common adverse effects of antipsychotic medications, World Psychiatry, 2018, 17, 341-356.
- 7) Berardi D, Giannelli A, Barnes TR, Clinical correlates of akathisia in acute psychiatric inpatients, Int Clin Psychopharmacol, 2000, 15, 215-219.
- 8) Seemuller F, Schennach R, Mayr A, Musil R, Jager M, Maier W, Klingenberg S, Heuser I, Klosterkotter J, Gastpar M, Schmitt A, Schlosser R, Schneider F, Ohmann C, Lewitzka U, Gaebel W, Moller HJ, Riedel M, Akathisia and suicidal ideation in first-episode schizophrenia, J Clin Psychopharmacol, 2012, 32, 694-698.
- 9) Hansen L, A critical review of akathisia, and its possible association with suicidal behaviour, Hum Psychopharmacol, 2001, 16, 495-505.
- 10) Juncal-Ruiz M, Ramirez-Bonilla M, Gomez-Arnau J, Ortiz-Garcia de la Foz V, Suarez-Pinilla P, Martinez-Garcia O, Neergaard KD, Tabares-Seisdedos R, Crespo-Facorro B, Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment, Psychopharmacology(Berl), 2017, 234, 2563-2570.
- 11) Miller CH, Hummer M, Oberbauer H, Kurzthaler I, DeCol C, Fleischhacker WW, Risk factors for the development of neuroleptic induced akathisia, Eur Neuropsychopharmacol, 1997, 7, 51-55.
- 12) Hansen LK, Nausheen B, Hart D, Kingdon D, Movement disorders in patients with schizophrenia and a history of substance abuse, Hum Psychophar-macol, 2013, 28, 192-197.
- 13) Thomas JE, Caballero J, Harrington CA, The Incidence of Akathisia in the Treatment of Schizo-phrenia with Aripiprazole, Asenapine and Lurasi-done: A Meta-Analysis, Curr Neuropharmacol, 2015, 13, 681-691.
- 14) Inada T, Inagaki A, Psychotropic dose equivalence in Japan, Psychiatry Clin Neurosci, 2015, 69, 440-447.
- 15) Nelson JC, Thase ME, Trivedi MH, Fava M, Han J, Van Tran Q, Pikalov A, Qi Y, Carlson BX, Marcus RN, Berman RM, Safety and Tolerability of Adjunc-tive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis(studies CN138-139 and CN138-163), Prim Care Companion J Clin Psychiatry, 2009, 11, 344-352.
- 16) Keck PE, Orsulak PJ, Cutler AJ, Sanchez R, Torbeyns A, Marcus RN, McQuade RD, Carson WH, Aripiprazole Monotherapy in the Treatment of Acute Bipolar I Mania: A Randomized, Double-Blind, Placebo- And Lithium-Controlled Study, J Affect Disord, 2009, 112, 36-49.
- 17) Tandon R, Marcus RN, Stock EG, Riera LC, Kostic D, Pans M, McQuade RD, Nyilas M, Iwamoto T, Crandall DT, A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric prac-tice: Broad Effectiveness Trial With Aripiprazole(BETA), Schizophr Res, 2006, 84, 77-89.
- 18) El Mallakh RS, Vieta E, Rollin L, Marcus R, Carson WH, McQuade R, A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I(manic or mixed) in subpopulations(CN138-007), Eur Neuropsychopharmacol, 2010, 20, 776-783.
- 19) Takeuchi H, Thiyanavadivel S, Agid O, Remington G, Rapid vs. slow antipsychotic initiation in schizo-phrenia: A systematic review and meta-analysis, Schizophr Res, 2018, 193, 29-36.
- 20) Yoshimura B, Sato K, Sakamoto S, Tsukahara M, Yoshimura Y, So R, Incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone: secondary analysis of an observational study, Psychopharmacology(Berl), 2019, 236, 723-730.
- 21) Lewis R, Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms, Can J Psychiatry, 1998, 43, 596-604.
- 22) Lencer R, Eismann G, Kasten M, Kabakci K, Geithe V, Grimm J, Klein C, Family history of primary movement disorders as a predictor for neuroleptic-induced extrapyramidal symptoms, Br J Psychiatry, 2004, 185, 465-471.
- 23) 上村 誠, 薬原性急性アカシジアの病態-薬原性錐体外路症状(EPS)と病態的に同根か-, 臨床精神薬理, 2002, 5, 39-45.
- 24) Benes FM, Taylor JB, Cunningham MC, Conver-gence and plasticity of monoaminergic systems in the medial prefrontal cortex during the postnatal period: implications for the development of psycho-pathology, Cereb Cortex, 2000, 10, 1014-1027.
- 25) Rehman HU, Masson EA, Neuroendocrinology of ageing, Age Ageing, 2001, 30, 279-287.
- 26) Hirose T, Kikuchi T, Aripiprazole, a novel antipsy-chotic agent: dopamine D2 receptor partial agonist, J Med Invest, 2005, 52, 284-290.
- 27) Erdur B, Tura P, Aydin B, Ozen M, Ergin A, Parlak I, Kabay B, A trial of midazolam vs diphenhydramine in prophylaxis of metoclopramide-induced akathisia, Am J Emerg Med, 2012, 30, 84-91.
- 28) Guina J, Merrill B, Benzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives, J Clin Med, 2018, 7, 17. doi: 10.3390/jcm7020017.
- 29) 中込和幸, 三島和夫, 中川敦夫, 稲垣 中, 伊藤弘人, 奥村泰之, 山之内芳雄, 石郷岡純, "向精神薬の処方実態に関する研究", 厚生労働科学研究費補助金障害者対策総合研究事業 平成26年度総括・分担研究報告書, 2015, pp9-26, pp75-89.
